Tag: PD-L1 inhibitor for uterine cancer

Home / PD-L1 inhibitor for uterine cancer

Categories

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer

  June 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with carboplatin and paclitaxel, followed by singl...
pd-l1-inhibitor-for-uterine-cancer

Scan the code